Abstracts tagged "Vasculitis"

Abstract Number: 1946 • ACR Convergence 2020
Fast-Track Giant Cell Arteritis Clinic Experience in the United States
Mark Matza¹, Minna Kohler², John H. Stone³ and Sebastian Unizony¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Fast-track clinics incorporating ultrasound into the initial evaluation of patients suspected of having giant cell arteritis (GCA) have been implemented throughout Europe leading to…
Abstract Number: 0424 • ACR Convergence 2020
Anti-Collagen II Antibodies in Patients with Relapsing Polychondritis
Kristina Wells¹, Marcela Ferrada², Emily Rose², Keith Sikora³, Wendy Goodspeed², Kaitlin Quinn⁴ and Peter C. Grayson⁵, ¹Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, ²Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³National Institutes of Health Clinical Center, Bethesda, MD, ⁴Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, ⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a highly heterogenous systemic inflammatory disorder that affects many organ systems, in particular, cartilaginous structures. Clinical presentations in RP are…
Abstract Number: 1422 • ACR Convergence 2020
Healthcare Utilization Among Patients Diagnosed with ANCA-Associated Vasculitis Between 2007 and 2014 in a Multi-Center Cohort Linked to Medicare Claims Data
Zachary Wallace¹, Xiaoqing Fu², John Stone³, Hyon Choi⁴ and Rochelle Walensky², ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Concord, MA, ⁴Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: ANCA-associated vasculitis (AAV) leads to complications that contribute to poor quality of life and survival. Systemic vasculitis is associated with high healthcare utilization but…
Abstract Number: 1688 • ACR Convergence 2020
Long-term Hearing Loss, Anxiety and Neurodevelopmental Outcomes Following Kawasaki Disease: A Population-based Cohort Study
Cal Robinson¹, Francis Lao², Rahul Chanchlani¹, Anastasia Gayowsky³, Sandeep Brar⁴, Elizabeth Darling⁵, Catherine Demers⁵, Tapas Mondal¹, Rulan Parekh⁶, Hsien Seow⁵ and Michelle Batthish¹, ¹McMaster Children's Hospital, Hamilton, ON, Canada, ²Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada, ³ICES McMaster, Hamilton, ON, Canada, ⁴University of California, San Fransisco, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Toronto, Toronto, Canada
Background/Purpose: The incidence of Kawasaki disease (KD) is increasing in Ontario. Cardiovascular sequelae following KD are well-described. However, there are limited and conflicting non-cardiovascular outcome…
Abstract Number: 1947 • ACR Convergence 2020
Risk Factors for Anxiety and Depression in Patients with Giant Cell Arteritis
Joana Martinho¹, André Ponte², Eduardo Dourado³, Nikita Khmelinskii¹, Sara Dias⁴, Sofia Barreira⁵, Ana Rita Cruz-Machado¹, Carla Macieira¹, Vítor Teixeira⁶, Ana Rodrigues⁴, Diogo Telles-Correia⁷, João Eurico Fonseca⁸ and Cristina Ponte¹, ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ²Centro Hospitalar Psiquiátrico de Lisboa, Lisboa, Portugal, Lisbon, Portugal, ³Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Lisboa, Portugal, ⁴EpiDoC Unit, Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School, Universidade NOVA de Lisboa (NMS/UNL), Lisbon, Portugal, ⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, ⁶Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ⁷Serviço de Psiquiatria, Hospital de Santa Maria, CHULN, Lisboa, Portugal, Lisbon, Portugal, ⁸Instituto de Medicina Molecular, Faculdade Medicina Universidade de Lisboa and Centro Hospitalar Universitário Lisboa Norte., Lisboa, Portugal
Background/Purpose: Giant cell arteritis (GCA) is the most common primary vasculitis affecting patients aged above 50 years. Its clinical manifestations such as headache, jaw claudication…
Abstract Number: 068 • 2020 Pediatric Rheumatology Symposium
Development of CARRA Consensus Treatment Plans for Severe ANCA-associated Vasculitis – Final CARRA-wide Consensus
Linda Wagner-Weiner ¹, Vidya Sivaraman ², Karen James ³, Eric Yen ⁴, Kathleen O'Neil ⁵, Dana Gerstbacher ⁶, Ann Marie Szymanski⁷, Kimberly Morishita ⁸ and David Cabral ⁹ for the CARRA investigators, ¹University of Chicago, Chicago, Illinois, ²Division of Rheumatology, Nationwide Children's Hospital, Bexley, ³University of Utah, 84113, Utah, ⁴UCLA, Los Angeles, California, ⁵University of Indiana School of Medicine, Indianapolis, Indiana, ⁶Stanford University School of Medicine, Palo Alto, California, ⁷Tampa, Florida, ⁸University of British Columbia - Vancouver, Vancouver, British Columbia, Canada, ⁹BC Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada
Background/Purpose: Randomized trials for pediatric ANCA-associated vasculitis (ped-AAV) have not been feasible because of its rarity, therefore adult treatment strategies are usually adapted for children.…
Abstract Number: 084 • 2020 Pediatric Rheumatology Symposium
Kawasaki Disease Shock Syndrome: A Single Center Cohort
Monica Bray¹, Jennifer Rammel ², Andrea Ramirez ³, Kristen Sexson ⁴, Fong Lam ⁵, Eyal Muscal ¹ and Marietta De Guzman ³, ¹Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, ²Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁴Section of Cardiology, Department of Pediatrics, Baylor College of Medicine, Houston, ⁵Section of Critical Care, Department of Pediatrics, Baylor College of Medicine, Houston
Background/Purpose: Kawasaki disease (KD) is a well described vasculitis of childhood that is the leading cause of acquired heart disease in developed countries. Kawasaki disease…
Abstract Number: 102 • 2020 Pediatric Rheumatology Symposium
Implications of Positive Tests for ANCA in a Pediatric Population
Karen James¹, Peter Merkel ² and Aimee Hersh ³, ¹University of Utah, 84113, Utah, ²University of Pennsylvania, Philadelphia, ³University of Utah Primary Children's Hospital, Salt Lake City
Background/Purpose: Testing for ANCA, particularly performed by ELISA (anti-MPO/PR3) is highly sensitive and specific for ANCA-associated vasculitis (AAV). However ANCA testing may be used in…
Abstract Number: 138 • 2020 Pediatric Rheumatology Symposium
Serious Infection Risk in Pediatric Patients with Low Immunoglobulin Levels Following Rituximab Treatment for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Simone Melega ¹, Paul Brogan², Gavin Cleary ³, Aimee Hersh ⁴, Ozgur Kasapcopur ⁵, Satyapal Rangaraj ⁶, Rae Yeung ⁷, Andrew Zeft ⁸, Jennifer Cooper ⁹, Pooneh Pordeli ¹⁰, Petra Kirchner ¹¹ and Patricia Lehane ¹², ¹F. Hoffmann-La Roche, Ltd., Basel, Switzerland, ²UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ³Alder Hey Children's Hospital, Liverpool, United Kingdom, ⁴University of Utah Primary Children's Hospital, Salt Lake City, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Cerrahpasa, Turkey, ⁶Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ⁷The Hospital for Sick Children, Toronto, Canada, ⁸The Cleveland Clinic - Center for Pediatric Rheumatology & Immunology, Cleveland, Ohio, ⁹University of Colorado, Children's Hospital Colorado, Denver, ¹⁰F. Hoffmann-La Roche, Ltd., Mississauga, Canada, ¹¹F. Hoffmann-La Roche Ltd., Birsfelden, Switzerland, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Low immunoglobulin (Ig) levels can occur after rituximab treatment, but the clinical significance is not completely understood. Not all patients (pts) who develop low…
Abstract Number: 051 • 2020 Pediatric Rheumatology Symposium
Pediatric Providers’ Perspectives on Suspected Immune-Mediated Diffuse Alveolar Hemorrhage and Clinical Care Pathways
Jessica Bloom¹ and Robert Fuhlbrigge ², ¹Children's Hospital Colorado, Aurora, Colorado, ²University of Colorado, Aurora
Background/Purpose: Immune-mediated diffuse alveolar hemorrhage (iDAH) is a life-threatening complication of pediatric rheumatologic diseases such as vasculitis, systemic lupus erythematosus, and antiphospholipid antibody syndrome. Delay…
Abstract Number: 1670 • 2019 ACR/ARP Annual Meeting
Evaluation of Subclinical Coronary Atherosclerosis in ANCA-associated Small Vessel Vasculitides (AAVs) Compared to Matched Controls Through Visual Assessment of Coronary Arterial Calcium (CAC) Score Using Non-Gated Chest Computed Tomography (CT)
Sohail Farshad¹, Alexandra Halalau ², Sayf Al-Katib ³, Julie George ⁴ and Elena Schiopu ⁵, ¹Department of Internal Medicine, Beaumont Health System, Royal Oak, MI, ²Department of Internal Medicine, Beaumont Health System, Royal Oak, ³Department of Radiology, Beaumont Health System, Royal Oak, MI, ⁴Beaumont Health System, Royal Oak, MI, ⁵Department of Rheumatology, University of Michigan, Ann Arbor
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is the most prevalent adult vasculitis and is associated with significant inflammatory burden; chest computed tomography (CT)…
Abstract Number: 2104 • 2019 ACR/ARP Annual Meeting
Vasculitis in HIV-Infected Individuals: Making the Case for an Antigen Driven Process
Courtney McCray¹, Gloria Salazar ², Ryan Valicek ¹, Binh Nguyen ³, Benjamin Naovarat ⁴, Francis Williams ² and John Reveille ², ¹University of Texas McGovern Medical School, Houston, TX, ²University of Texas McGovern Medical School, Houston, ³University of Texas McGoven Medical School, Houston, ⁴University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: A large spectrum of vasculitides affecting small, medium, and large vessels have been reported in HIV-infected individuals. Although vasculitis is a rare manifestation of…
Abstract Number: 1671 • 2019 ACR/ARP Annual Meeting
Hospital Admissions and Mortality in Patients with ANCA-associated Vasculitis
Jon Golenbiewski¹, Amanda Eudy ², Megan Clowse ² and Nancy Allen ², ¹Duke University, Durham, NC, ²Duke University, Durham
Background/Purpose: ANCA-associated vasculitis (AAV) has a high rate of complications, both from disease itself and treatments. Hospital mortality rates for AAV range between 10-20%. There…
Abstract Number: 2281 • 2019 ACR/ARP Annual Meeting
The Vasculitis Pregnancy Registry (V-PREG): Information from the First 3 Years
Jon Golenbiewski¹, Kalen Young ², Cristina Burroughs ³, Joyce Kullman ², Peter Merkel ⁴ and Megan Clowse ⁵, ¹Duke University Medical Center, Durham, NC, ²Vasculitis Foundation, Kansas City, MO, ³University of South Florida, Tampa, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Duke University, Durham
Background/Purpose: As outcomes for patients with vasculitis improve and treatments become less ovarian-toxic, more women with these diseases will become pregnant. How best to manage…
Abstract Number: 1675 • 2019 ACR/ARP Annual Meeting
A Retrospective Cohort Study Using Clinical Notes and Latent Topic Modeling to Characterize the Natural History of ANCA-Associated Vasculitis
Liqin Wang¹, Eli Miloslavsky ², John Stone ³, Hyon K. Choi ⁴, Li Zhou ⁵ and Zachary Wallace ², ¹Brigham and Women's Hospital, Boston, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) is associated with end-organ damage, complications of treatment, and excess death. Retrospective studies on the clinical course of AAV, including the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.